Evidence map›Paper›PMID 41307819›Full record

ReviewJournal of gastrointestinal cancer2025

Radioembolization in Hepatocellular Carcinoma: Indications and Outcomes.

Bahareh Gholami, Ali Afrasiabi, Paolo Varela, Samira Gholami, Andrew Moon, Alexander Villalobos, David Mauro, Bryan Harris, Hyeon Yu, Nima Kokabi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bahareh GholamiDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, USA.
Ali AfrasiabiDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, USA.
Paolo VarelaDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, USA.
Samira GholamiShahid Beheshti University of Medical Sciences, Tehran, Iran.
Andrew MoonDivision of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, USA.
Alexander VillalobosDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, USA.
David MauroDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, USA.
Bryan HarrisDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, USA.
Hyeon YuDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, USA.
Nima KokabiDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, USA. nima_kokabi@med.unc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) continues to rank among the most common causes of cancer-associated deaths, especially since a large number of patients cannot undergo curative resection or transplantation. For HCC patients, transarterial radioembolization (TARE) with yttrium-90 microspheres has become a rapidly emerging multipurpose treatment. For patients with early-stage disease, radiation segmentectomy, which is frequently used as a bridge or downstaging strategy to transplant, is a curative-intent treatment comparable to thermal ablation. For patients with inadequate future liver remnant, radiation lobectomy is a two-fold solution to local tumor control and hypertrophy of the resectable contralateral liver. TARE, in the intermediate and advanced stages of HCC, provides long-term disease control and maintains liver function, and is frequently used as an alternative or in combination with systemic treatment. Personalized dosimetry is an advancement in treatment planning, and the combination of TARE with immunotherapy is a promising area of exploration. Overall, the evolution of radio-embolization from a purely palliative to a disease-modifying curative option, greater use in more stages of the disease, and more positive outcomes than in the past, marks a significant achievement in the treatment of HCC.

Indexed as

Carcinoma, HepatocellularEmbolization, TherapeuticLiver NeoplasmsYttrium RadioisotopesHumansTreatment OutcomeYttrium-90Yttrium RadioisotopesBarcelona Clinic Liver CancerHepatocellular carcinomaMicrowave ablationTransarterial chemoembolizationTransarterial radioembolization

Identifiers

PMID41307819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.